New CAR T approach minimizes resistance, helps avoid relapse in non-Hodgkin's B-cell lymphoma

Early results from a new, pioneering chimeric antigen receptor (CAR) T cell immunotherapy trial found using a bilateral attack achieves a more robust defense and helps avoid relapse.

from Top Health News -- ScienceDaily https://ift.tt/3a0u1KU